Zobrazeno 1 - 10
of 188
pro vyhledávání: '"Geert, D'Haens"'
Autor:
Laurent Peyrin-Biroulet, Jean-Frederic Colombel, Edouard Louis, Marc Ferrante, Satoshi Motoya, Remo Panaccione, Joana Torres, Ryan C. Ungaro, Kristina Kligys, Jasmina Kalabic, Javier Zambrano, Yafei Zhang, Geert D'Haens
Publikováno v:
Gastro Hep Advances, Vol 3, Iss 4, Pp 539-550 (2024)
Background and Aims: Early biologic therapy treatment has demonstrated better outcomes in Crohn’s disease (CD). We evaluated the impact of CD duration in patients with moderately to severely active CD treated with risankizumab therapy. Methods: Thi
Externí odkaz:
https://doaj.org/article/fa55166e9c4e42f79099e540030db28a
Autor:
Ishtu Hageman, Femke Mol, Sadaf Atiqi, Vincent Joustra, Hilal Sengul, Peter Henneman, Ingrid Visman, Theodorus Hakvoort, Mike Nurmohamed, Gertjan Wolbink, Evgeni Levin, Andrew Y.F. Li Yim, Geert D’Haens, Wouter J. de Jonge
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Background and aimsRheumatoid arthritis (RA) patients are currently treated with biological agents mostly aimed at cytokine blockade, such as tumor necrosis factor-alpha (TNFα). Currently, there are no biomarkers to predict therapy response to these
Externí odkaz:
https://doaj.org/article/499f4a55150d46dd8f718dd216142698
Autor:
Vincent Joustra, Andrew Y.F. Li Yim, Ishtu Hageman, Evgeni Levin, Alex Adams, Jack Satsangi, Wouter J. de Jonge, Peter Henneman, Geert D’Haens
Publikováno v:
Cellular and Molecular Gastroenterology and Hepatology, Vol 15, Iss 4, Pp 869-885 (2023)
Background & Aims: There is great current interest in the potential application of DNA methylation alterations in peripheral blood leukocytes (PBLs) as biomarkers of susceptibility, progression, and treatment response in inflammatory bowel disease (I
Externí odkaz:
https://doaj.org/article/f4da3dfe0cbe411593eca99d4377a2f6
Publikováno v:
Inflammatory Intestinal Diseases, Pp 1-1 (2023)
Introduction: High-strength mesalazine formulations play an important role in providing a convenient option to increase the dose in ulcerative colitis (UC) patients and therefore avoiding the switch to another therapeutic class. Higher doses of mesal
Externí odkaz:
https://doaj.org/article/70f95bd183ff402486d0bf9bdddd46d3
Autor:
Adriaan Volkers, Mark Löwenberg, Marlou Braad, Yara Abeling, Krisztina Gecse, Nicole Berkers, Nahid Montazeri, Geert D’Haens
Publikováno v:
Diagnostics, Vol 13, Iss 10, p 1712 (2023)
Background and aims: Point-of-care tests (POCT) allow instant measurement of inflammatory markers and drug concentrations. Here, we studied agreement between a novel POCT device and reference methods of measuring infliximab (IFX) and adalimumab (ADL)
Externí odkaz:
https://doaj.org/article/e6448056111e4d56bdf6bcebc9eaf899
Autor:
Vincent W. Joustra, Andrew Y. F. Li Yim, Jessica R. de Bruyn, Marjolijn Duijvestein, Ishtu L. Hageman, Wouter J. de Jonge, Peter Henneman, Manon Wildenberg, Geert D’Haens
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 18, p 10467 (2022)
Prediction of endoscopic post-operative recurrence (POR) in Crohn’s disease (CD) patients following ileocolonic resection (ICR) using clinical risk factors alone has thus far been inadequate. While peripheral blood leukocyte (PBL) DNA methylation h
Externí odkaz:
https://doaj.org/article/7db02ab23c0c44aea4813b64d0c0967d
Autor:
Edward V. Loftus, Julian Panés, Ana P. Lacerda, Laurent Peyrin-Biroulet, Geert D’Haens, Remo Panaccione, Walter Reinisch, Edouard Louis, Minhu Chen, Hiroshi Nakase, Jakob Begun, Brigid S. Boland, Charles Phillips, Mohamed-Eslam F. Mohamed, Jianzhong Liu, Ziqian Geng, Tian Feng, Elena Dubcenco, Jean-Frederic Colombel
Publikováno v:
New England Journal of Medicine. 388:1966-1980
Autor:
William J Sandborn, Séverine Vermeire, Laurent Peyrin-Biroulet, Marla C Dubinsky, Julian Panes, Andres Yarur, Timothy Ritter, Filip Baert, Stefan Schreiber, Sheldon Sloan, Fabio Cataldi, Kevin Shan, Christopher J Rabbat, Michael Chiorean, Douglas C Wolf, Bruce E Sands, Geert D'Haens, Silvio Danese, Martina Goetsch, Brian G Feagan
Publikováno v:
The Lancet, 401(10383), 1159-1171. Elsevier Limited
BACKGROUND: Etrasimod, a once-daily, oral, sphingosine 1-phosphate (S1P) receptor modulator that selectively activates S1P receptor subtypes 1, 4, and 5, with no detectable activity on S1P2,3, is in development for the treatment of immune-mediated di
Efficacious dosing regimens for anti-TNF therapies in inflammatory bowel disease: where do we stand?
Publikováno v:
Expert Opinion on Biological Therapy. 23:341-351
Introduction: During the last decades, biologics have revolutionized the treatment of Crohn’s disease and ulcerative colitis. Even though the inflammatory bowel disease (IBD) armamentarium is rapidly expanding with novel biologics, anti-tumor necro
Autor:
Geert D’Haens, Walter Reinisch, Stefan Schreiber, Fraser Cummings, Peter M. Irving, Byong Duk Ye, Dong-Hyeon Kim, SangWook Yoon, Shomron Ben-Horin
Publikováno v:
Clinical drug investigation, 43(4), 277-288. Adis International Ltd
Background and Objective: Whether benefits and risks of intravenous (IV) infliximab combotherapy with immunosuppressants versus infliximab monotherapy apply to subcutaneous (SC) infliximab is unknown. This post hoc analysis of a pivotal randomised CT